Kinnate Biopharma Inc.
$2.65▼ 0.38%($-0.01)
TickerSpark Score
68/100
▌ Solid
80
Valuation
35
Profitability
40
Growth
84
Health
100
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNTE research report →
52-Week Range26% of range
Low
$1.04
Current
$2.65
High
$7.18
Company Overviewwww.kinnate.com
About the company
Kinnate Biopharma Inc. is a U. S.
- CEO
- Nima Farzan
- IPO
- 2020
- Employees
- 84
- HQ
- San Francisco, CA, US
Price Chart
-61.26% · this period
Valuation
- Market Cap
- $124.99M
- P/E
- -1.10
- P/S
- 0.00
- P/B
- 0.77
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.86%
- ROIC
- -73.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-112,649,000 · 1.20%
- EPS
- $-2.42 · 6.56%
- Op Income
- $-119,008,000
- FCF YoY
- -9.04%
Performance & Tape
- 52W High
- $7.18
- 52W Low
- $1.04
- 50D MA
- $2.49
- 200D MA
- $2.25
- Beta
- 1.34
- Avg Volume
- 367.16K
Get TickerSpark's AI analysis on KNTE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Form 4 · Filings
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 3, 24 | Tananbaum James B. | sell | 40,501 |
| Apr 3, 24 | Tananbaum James B. | sell | 20,250 |
| Apr 3, 24 | Tananbaum James B. | sell | 520,711 |
| Apr 3, 24 | Farzan Nima | sell | 750,000 |
| Apr 3, 24 | Farzan Nima | sell | 275,000 |
| Apr 3, 24 | Farzan Nima | sell | 2,186 |
| Apr 3, 24 | Farzan Nima | sell | 1,281,642 |
| Apr 3, 24 | Farzan Nima | sell | 400,000 |
| Apr 3, 24 | Farzan Nima | sell | 437,413 |
| Apr 3, 24 | MITCHELL DEAN J | sell | 20,250 |
Coverage · KNTE
Our KNTE coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on KNTE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNTE report →Internal Compare
Similar companies
Peers in the same neighborhood.
NGM▼1.28%
NGM Biopharmaceuticals, Inc.
$1.54
GRAY▼10.80%
Graybug Vision, Inc.
$5.50
DBTX▼0.81%
Decibel Therapeutics, Inc.
$4.91
PRTK▲1.83%
Paratek Pharmaceuticals, Inc.
$2.23
TRML▲0.00%
Tourmaline Bio, Inc.
$47.98
ATYR▲0.46%
aTyr Pharma, Inc.
$0.59
RVLP▼32.05%
RVL Pharmaceuticals plc
$0.03
PRDS▲0.93%
Pardes Biosciences, Inc.
$2.18